A series of opioid and serotonin re-uptake inhibitors (SSRIs) bifunctional ligands have been designed, synthesized, and tested for their activities and efficacies at μ-, δ- and κ opioid receptors and SSRIs receptors. Most of the compounds showed high affinities for μ- and δ-opioid receptors and lower affinities for SSRIs and κ opioid receptors. A docking study on the μ-opioid receptor binding pocket has been carried out for ligands 3-11. The ligands 7 and 11 have displayed the highest binding profiles for the μ-opioid receptor binding site with ΔGbind (-12.14kcal/mol) and Ki value (1.0nM), and ΔGbind (-12.41kcal/mol) and Ki value (0.4nM), respectively. Ligand 3 was shown to have the potential of dual acting serotonin/norepinephrine re-uptake inhibitor (SNRI) antidepressant activity in addition to opioid activities, and thus could be used for the design of multifunctional ligands in the area of a novel approach for the treatment of pain and depression.
Design, synthesis, and biological evaluation of a series of bifunctional ligands of opioids/SSRIs.
Reference
Munawar, Munawar A, et al. “Design, Synthesis, and Biological Evaluation of a Series of Bifunctional Ligands of Opioids SSRIs”. Bioorg Med Chem, vol. 23, no. 6, Jan. 2015, pp. 1251-9, https://doi.org/10.1016/j.bmc.2015.01.047.
Abstract